29.11.2023 - Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic . Seite 1
Harrow Announces Third Quarter 2023 Financial Results lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Operator: Good afternoon, and welcome to Harrow s Third Quarter 2023 Earnings Conference Call. My name is Betsy, and I will be your operator for today s call.
Harrow completes transfer of NDAs for several ophthalmic products healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.